Role of cytoreductive nephrectomy in the Era of targeted therapy for renal cell carcinoma

Current Urology Reports

Volumn 13, Issue 1, 2012, Pages 38-46

  Crispen, Paul L ^a   Blute, Michael L ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cytoreductive nephrectomy; Kidney diseases; Metastasectomy; Renal cell carcinoma; Surgery; Targeted therapy; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADRENAL METASTASIS; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURGERY; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; HUMAN; INTESTINE CANCER; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SAFETY; PREOPERATIVE CARE; PROGNOSIS; RETROPERITONEAL CANCER; REVIEW; SYSTEMIC THERAPY; VASCULAR TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84857564596     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-011-0225-x     Document Type: Review

References (44)

1. C Jeldres S Baillargeon-Gagne D Liberman, et al. 2009 A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States Urology 74 837 841 19616828
2. L Zini U Capitanio P Perrotte, et al. 2009 Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma Urology 73 342 346 19041122
3. RC Flanigan SE Salmon BA Blumenstein, et al. 2001 Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655 1659 11759643 1:CAS:528: DC%2BD3MXovFKjt74%3D (Pubitemid 33126820)
4. GH Mickisch A Garin H van Poppel L de Prijck R Sylvester 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966 970 11583750 1:CAS:528:DC%2BD3MXntF2qtbw%3D (Pubitemid 32913522)
5. RC Flanigan G Mickisch R Sylvester C Tangen H Van Poppel ED Crawford 2004 Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 1071 1076 14767273 (Pubitemid 38327529)
6. PN Lara Jr CM Tangen SJ Conlon RC Flanigan ED Crawford 2009 Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 J Urol 181 512 516 19100570
7. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 17215529 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
8. BI Rini S Halabi JE Rosenberg, et al. 2010 Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2137 2143 20368558 1:CAS:528:DC%2BC3cXpsFSgsbw%3D
9. B Escudier J Bellmunt S Negrier, et al. 2010 Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2144 2150 20368553 1:CAS:528:DC%2BC3cXpsFSgsbo%3D
10. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
11. CN Sternberg ID Davis J Mardiak, et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061 1068 20100962 1:CAS:528:DC%2BC3cXktF2lt78%3D
12. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
13. SH Culp NM Tannir EJ Abel, et al. 2010 Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116 3378 3388 20564061
14. SL Richey SH Culp E Jonasch, et al. 2011 Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy Ann Oncol 22 048 053 This article provides data on patients treated with targeted therapy alone and prognostic factors in this patient population
15. RJ Motzer RM Bukowski RA Figlin, et al. 2008 Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 1552 1558 18720362 1:CAS:528:DC%2BD1cXht1Ggu7bO
16. PI Karakiewicz M Sun J Bellmunt V Sneller B Escudier 2011 Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria Eur Urol 60 48 56 21190790
17. DY Heng W Xie MM Regan, et al. 2009 Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 5794 5799 19826129 1:CAS:528:DC%2BC3cXhtVWitr4%3D The data provided in this article can be extremely useful for risk stratification of patients receiving targeted therapy for metastatic renal cancer
18. TK Choueiri JA Garcia P Elson, et al. 2007 Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 543 550 17577222 1:CAS:528:DC%2BD2sXpt1yqu70%3D (Pubitemid 47106142)
19. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011; In press.
20. D You IG Jeong JH Ahn, et al. 2011 The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy J Urol 185 54 59 21074811
21. TK Choueiri W Xie C Kollmannsberger, et al. 2011 The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 60 66 21074201 This article provides initial data on the potential benefit of cytoreductive nephrectomy in patients receiving targeted therapy
22. P Russo 2010 Multi-modal treatment for metastatic renal cancer: the role of surgery World J Urol 28 295 301 20364382
23. JA Karam CG Wood 2011 The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy Hematol Oncol Clin North Am 25 753 764 21763966
24. AL Alt SA Boorjian CM Lohse BA Costello BC Leibovich ML Blute 2011 Survival after complete surgical resection of multiple metastases from renal cell carcinoma Cancer 117 2873 2882 21692048 This article provides detailed data and discussion on the benefit of complete metastasectomy in metastatic renal cancer
25. G Di Lorenzo C Porta J Bellmunt, et al. 2011 Toxicities of targeted therapy and their management in kidney cancer Eur Urol 59 526 540 21277078
26. J Barbastefano JA Garcia P Elson, et al. 2010 Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy BJU Int 106 1266 1269 20346042 1:CAS:528:DC%2BC3cXhsFyhtL3E
27. JA Karam BI Rini L Varella, et al. 2011 Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma J Urol 185 439 444 21167518
28. A Bex E Jonasch Z Kirkali, et al. 2010 Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials Eur Urol 58 819 828 20828919
29. A Kutikov RG Uzzo A Caraway, et al. 2009 Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy BJU Int 106 218 223 19922542
30. •• Chapin BF, Delacroix SE, Jr., Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;In press. This article is an extremely insightful description of postoperative complications in patients receiving presurgical therapy and provides initial outcome data.
31. T Powles I Kayani C Blank, et al. 2011 The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer Ann Oncol 22 1041 1047 21242586 1:STN:280:DC%2BC3MvmsVeguw%3D%3D
32. WK Rathmell R Pruthi E Wallen 2010 Neoadjuvant treatment of renal cell carcinoma Urol Oncol 28 69 73 20123351 1:CAS:528:DC%2BC3cXoslyl
33. AA Thomas BI Rini BR Lane, et al. 2009 Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 518 523 19100579 1:CAS:528:DC%2BD1MXitVWiu7g%3D
34. EJ Abel SH Culp NM Tannir, et al. 2011 Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma Eur Urol 59 10 15 20952123
35. CG Wood V Margulis 2009 Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease Cancer 115 2355 2360 19402066
36. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011; In press.
37. RJ Karnes ML Blute 2008 Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus Nat Clin Pract Urol 5 329 339 18477994 (Pubitemid 351818885)
38. NG Cost SE Delacroix Jr JP Sleeper, et al. 2011 The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus Eur Urol 59 912 918 21367518 1:CAS:528:DC%2BC3MXlsVCmsr8%3D
39. Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol. 2011; In press.
40. Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011; In press.
41. AJ Polcari A Gorbonos JE Milner RC Flanigan 2009 The role of cytoreductive nephrectomy in the era of molecular targeted therapy Int J Urol 16 227 233 19207114
42. PE Spiess MN Fishman 2010 Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma Cancer Control 17 269 278 20861814
43. E Chiong CG Wood V Margulis 2009 Role of cytoreductive nephrectomy in renal cell carcinoma Future Oncol 5 859 869 19663735
44. EJ Abel SH Culp SF Matin, et al. 2010 Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment J Urol 184 1877 1881 20850148